Andre Chen, MD
Addiction Medicine · Round Rock, TXNPI 1902871221
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.1% of the total across 116 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 34 manufacturers reported payments, led by Abbott at 44.6% of the total. Reporting peaked in 2024 at $1,166 and has fallen 66.9% since, to $386 in 2025.
Across 116 payments — averaging $37.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Amgen$419
- Teva Pharmaceuticals USA, Inc.$252
- SPR Therapeutics, Inc$183
- Indivior Inc.$145
- AbbVie$143
- plus $1K from 28 others
What the payments were for
- Food & beverage$4,30698%
- Education$842%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 30 | $1,960 |
| Amgen(2 entities) | 17 | $419 |
| Teva Pharmaceuticals USA, Inc. | 4 | $252 |
| SPR Therapeutics, Inc | 2 | $183 |
| Indivior Inc. | 2 | $145 |
| AbbVie | 5 | $143 |
| Biodelivery Sciences International, Inc. | 3 | $133 |
| Hikma Pharmaceuticals USA | 6 | $117 |
| Scilex Pharmaceuticals Inc. | 2 | $106 |
| Tonix Medicines, Inc. | 1 | $84 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $80 |
| Pfizer | 5 | $72 |
| Kaleo, Inc. | 2 | $60 |
| UCB, Inc. | 2 | $56 |
| Collegium Pharmaceutical, Inc. | 4 | $56 |
| Arbor Pharmaceuticals, Inc. | 4 | $54 |
| Johnson & Johnson | 2 | $52 |
| Biohaven Pharmaceuticals, Inc. | 3 | $51 |
| Baudax Bio Inc. | 1 | $50 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $40 |
| Radius Health, Inc. | 2 | $35 |
| MML US, Inc. | 1 | $27 |
| ANI Pharmaceuticals, Inc. | 1 | $26 |
| Pylant Medical | 1 | $25 |
| Orexo US, Inc. | 1 | $23 |
| Redhill Biopharma Inc. | 1 | $22 |
| Alkermes, Inc. | 1 | $21 |
| Medtronic | 1 | $21 |
| GRT US Holding, Inc. | 1 | $17 |
| Novartis | 1 | $13 |
| Emergent Biosolutions Inc. | 1 | $13 |
| Boston Scientific | 1 | $12 |
| IBSA Pharma Inc. | 1 | $12 |
| Pernix Therapeutics Holdings, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,390 in reported general payments places this provider in the 80th percentile of 42 addiction medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 1,984 | $209,226 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 61 | $31,043 |
| BelbucaBuprenorphine Hcl | 27 | $21,389 |
| NucyntaTapentadol Hcl | 14 | $13,754 |
| Buprenorphine Hcl | 616 | $11,828 |
| Gabapentin | 655 | $8,440 |
| Buprenorphine | 25 | $7,748 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 331 | $7,649 |
| Nucynta ErTapentadol Hcl | 13 | $7,024 |
| Lidocaine | 57 | $5,893 |
| MovantikNaloxegol Oxalate | 11 | $4,382 |
| Pregabalin | 211 | $4,374 |
| Diclofenac Sodium | 59 | $4,079 |
| Tizanidine Hcl | 294 | $2,703 |
| Duloxetine Hcl | 127 | $2,159 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Hikma Pharmaceuticals USABuprenorphine-Naloxone, Buprenorphine Hcl, Buprenorphine | $117 | $228,8022,625 claims |
| Collegium Pharmaceutical, Inc.Belbuca, Nucynta, Nucynta Er | $56 | $42,16754 claims |
| Orexo US, Inc.Zubsolv | $23 | $31,04361 claims |
| Redhill Biopharma Inc.Movantik | $22 | $4,38211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 42 addiction medicine providers in Texas.
Other addiction medicine in Round Rock
- Thomas KostenHouston$85K
- Carroll ThornburgEl Paso$33K
- Gloria MaguadogHouston$14K
- Charles IrwinDallas$11K
- Rany CherianBryan$6K
- Bo AllaireBellaire$6K
- James LaiHouston$6K
- Jeffrey ButtsBoerne$4K
- Michael SprintzHouston$2K
- Laura HoustonEl Paso$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.